xml version="1.0" encoding="UTF-8"?


C\_2019058EN.01001301.xml


| | | | |
| --- | --- | --- | --- |
| 14.2.2019 | EN | Official Journal of the European Union | C 58/13 |

---

Prior notification of a concentration

(Case M.9277 — Nalka Invest/OneMed)

Candidate case for simplified procedure

(Text with EEA relevance)

(2019/C 58/12)

1.

On 5 February 2019, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 [(1)](#ntr1-C_2019058EN.01001301-E0001).

This notification concerns the following undertakings:

| | |
| --- | --- |
| — | Nalka Invest AB (‘Nalka Invest’, Sweden), belonging to the Interogo Group, which is ultimately controlled by the Interogo Foundation (Liechtenstein); |

| | |
| --- | --- |
| — | OneMed AB (‘OneMed’, Sweden). |

Nalka Invest, through its portfolio company Strukturfonden HC15 AB, acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of OneMed. The concentration is accomplished by way of purchase of shares.

2.

The business activities of the undertakings concerned are:

—   for Nalka Invest: a Swedish investment company controlling Strukturfonden HC15 AB that invests in small and medium-sized companies mainly in the Nordics, aiming to invest in different industries and to have a diversified portfolio;

—   for Interogo Group: comprises IKEA Holding B.V. (the Netherlands), which has several business areas related to the IKEA furniture business, and Interogo Holding AG (Switzerland), an investment company which focuses on property investments and financial investments;

—   for OneMed: provides services, support systems and medical supplies to health care providers in the Nordics, Baltics and Netherlands.

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 [(2)](#ntr2-C_2019058EN.01001301-E0002) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.9277 — Nalka Invest/OneMed

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

| |
| --- |
| Email: COMP-MERGER-REGISTRY@ec.europa.eu |
| Fax +32 22964301 |
| Postal address: |
| European Commission |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

---

[(1)](#ntc1-C_2019058EN.01001301-E0001)  [OJ L 24, 29.1.2004, p. 1](http://publications.europa.eu/resource/oj/JOL_2004_024_R_TOC) (the ‘Merger Regulation’).

[(2)](#ntc2-C_2019058EN.01001301-E0002)  [OJ C 366, 14.12.2013, p. 5](http://publications.europa.eu/resource/oj/JOC_2013_366_R_TOC).

---